- Trials with a EudraCT protocol (271)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
271 result(s) found for: MDD AND Major Depressive Disorder.
Displaying page 11 of 14.
EudraCT Number: 2007-006127-12 | Sponsor Protocol Number: PNB/CPS 02 2007 | Start Date*: 2008-01-22 |
Sponsor Name:PharmaNeuroBoost N.V. (PNB) | ||
Full Title: Pipamperone/Citalopram (PipCit) versus Citalopram in the Treatment of Major Depressive disorder (MDD) | ||
Medical condition: Major Depressive Disorder (MDD) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002067-14 | Sponsor Protocol Number: 3151A6-2001 | Start Date*: 2015-04-03 |
Sponsor Name:Wyeth Research | ||
Full Title: 6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent O... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-002066-57 | Sponsor Protocol Number: 3151A6-2000 | Start Date*: 2015-04-03 |
Sponsor Name:Wyeth Research | ||
Full Title: Multicenter, Open-Label, Safety, Tolerability, and Pharmacokinetic Study to Evaluate Single Ascending Doses and Subsequent Short-Term Administration of Fixed Doses of Desvenlafaxine Succinate Susta... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-001209-26 | Sponsor Protocol Number: 01032012 | Start Date*: 2013-10-11 | |||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||
Full Title: Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in... | |||||||||||||
Medical condition: Major Depression ICD10: F 32.1, F 32.2, F32.3, F33.1, F33.2, F33.3 Klassifikationscode MedDRA : 10012378 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000562-13 | Sponsor Protocol Number: 3151A1-309-EU | Start Date*: 2004-07-26 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development | ||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | ||
Medical condition: Major depressive disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004422-42 | Sponsor Protocol Number: ESKETINSUI2002 | Start Date*: 2017-10-02 | ||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
Full Title: A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensiv... | ||||||||||||||||||||||||||||
Medical condition: Major Depressive Disorder with Imminent Risk of Suicide | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: HU (Completed) ES (Restarted) BE (Completed) PL (Completed) IT (Completed) BG (Completed) FR (Completed) Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005878-37 | Sponsor Protocol Number: 039(C)SC11063 | Start Date*: 2012-06-05 | |||||||||||||||||||||
Sponsor Name:ANGELINI | |||||||||||||||||||||||
Full Title: A randomized, double-blind study comparing the efficacy and safety of trazodone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder | |||||||||||||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) AT (Completed) CZ (Completed) ES (Completed) SK (Completed) RO (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001637-27 | Sponsor Protocol Number: LQD | Start Date*: 2016-09-20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:South London and Maudsley NHS Foundation Trust [...] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Treatment resistant major depressive disorder (single episode or recurrent). Treatment resistant depression, defined as failure to respond to two or more adequate doses of antidepressant in the cur... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005457-25 | Sponsor Protocol Number: PCN-101-21 | Start Date*: 2021-08-30 | |||||||||||
Sponsor Name:Perception Neuroscience, Inc | |||||||||||||
Full Title: A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression | |||||||||||||
Medical condition: Treatment-resistant depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000719-26 | Sponsor Protocol Number: ETS6103-003 | Start Date*: 2013-06-10 | |||||||||||
Sponsor Name:e-Therapeutics plc | |||||||||||||
Full Title: A single centre, double blind, non-inferiority study to evaluate the antidepressant activity of Viotra™ compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients w... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000064-28 | Sponsor Protocol Number: RAP-MD-33 | Start Date*: 2018-11-28 | |||||||||||
Sponsor Name:Allergan Ltd. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder | |||||||||||||
Medical condition: Major depressive disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019556-44 | Sponsor Protocol Number: CL3-20098-073 | Start Date*: 2010-09-03 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel gr... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000229-19 | Sponsor Protocol Number: 15905A | Start Date*: 2014-09-19 | |||||||||||
Sponsor Name:H. Lundbeck A/S | |||||||||||||
Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled study on the efficacy of vortioxetine on cognitive dysfunction in patients with partial or full remission of major de... | |||||||||||||
Medical condition: Major Depressive Disorder and cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) DE (Completed) FI (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024632-42 | Sponsor Protocol Number: H9P-MC-LNBN | Start Date*: 2011-05-05 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: LY2216684 compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder | |||||||||||||
Medical condition: major depressive disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) SK (Completed) GR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003992-23 | Sponsor Protocol Number: 54135419SUI3002 | Start Date*: 2017-07-26 | ||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto... | ||||||||||||||||||||||||||||
Medical condition: Major Depressive Disorder with Imminent Risk of Suicide | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) PL (Completed) CZ (Completed) AT (Completed) LT (Completed) FR (Completed) ES (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000567-77 | Sponsor Protocol Number: 42847922MDD1016 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have ... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA ES (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004122-17 | Sponsor Protocol Number: iSPOT-D | Start Date*: 2008-08-29 |
Sponsor Name:BRC operations Pty. Ltd. | ||
Full Title: International Study to Predict Optimised Treatment - in Depression iSPOT-D | ||
Medical condition: Patients suffering from major depressive disorder (MDD) as well as healthy control participants. Only patients will receive medication which will be 'treatment as usual'. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-004905-17 | Sponsor Protocol Number: PIR112487 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-010188-18 | Sponsor Protocol Number: 26859 | Start Date*: 2010-07-01 |
Sponsor Name:Eli Lilly Nederland | ||
Full Title: Effectiveness of Transmural Collaborative care and Duloxetine for major depressive disorder and (sub)chronic pain: a randomized placebo-controlled Multi-Centre trial. | ||
Medical condition: Major depressive disorder (episode or recurrent), as principal DSM-IV diagnosis combined with (sub)chronic pain symptoms as defined bij score of >3 on BPI painlist for at least six weeks. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002992-33 | Sponsor Protocol Number: 54135419TRD3013 | Start Date*: 2020-08-04 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared Wit... | |||||||||||||
Medical condition: Treatment-Resistant Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) CZ (Completed) PL (Completed) DE (Completed) HU (Completed) FR (Completed) BE (Completed) PT (Completed) BG (Completed) DK (Completed) AT (Completed) NO (Completed) FI (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
